Compare Cassava Sciences Inc (FLNA) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Vanguard Total Stock Market Index Fund ETF trades at $380.78 (market cap $2.30T). The key difference: Vanguard Total Stock Market Index Fund ETF is far larger — about 58375.6× Cassava Sciences Inc's market cap, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Vanguard Total Stock Market Index Fund ETF for 131 Days on average.
| FLNA | VTI | |
|---|---|---|
Market Cap | $39.40M | $2.30T |
Volume | 759,018 | 2,982,924 |
Sector | Health | — |
52-Week High | $4.64 | $384.30 |
52-Week Low | $0.68 | $311.68 |
Typical Hold Time | 37 Days | 131 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
VTI trades at $380.52, down slightly by 0.13% with a bullish technical signal from moving averages. The ETF maintains broad U.S. equity exposure across 3,500+ stocks, though concentration in top holdings remains significant. Recent news highlights long-term growth potential with $500 monthly investments since 2001 growing to approximately $876,000 according to Motley Fool (2026-10-01).
VTI offers diversified U.S. market access with low costs, suitable for long-term investors. Risks include market concentration in top holdings and broader economic sensitivity. Analyst sentiment remains positive for buy-and-hold strategies, though recent articles question the value added by small/mid-cap exposure versus S&P 500-focused alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
